Skip to main content
Top
Published in: Endocrine 2/2017

01-11-2017 | Original Article

Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center

Authors: Jekaterina Patrova, Magnus Kjellman, Hans Wahrenberg, Henrik Falhammar

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

Purpose

To compare long-term outcomes in patients with adrenal incidentalomas (AIs) with the response to a 1 mg overnight dexamethasone suppression test (DST).

Methods

Consecutive patients with “non-functional” AIs (n = 365) were examined. Patients with overt hormone excess, adrenocortical cancer and known malignancy had been excluded. Patients were classified to normal cortisol secretion group (n = 204, DST ≤ 50 nmol/l), possible autonomous cortisol secretion group (n = 128, DST 51–138 nmol/l) and autonomous cortisol secretion group (n = 33, DST ≥ 138 nmol/l).

Results

Thirty-seven patients (10.1%) deceased during the follow-up period (5.2 ± 2.3 years): 16(7.8%) in the non-secreting group (time from diagnosis to death: 3.9 ± 2.9 years), 15 in the possible autonomous cortisol secretion group (11.7%, 3.2 ± 1.8 years) and 6 in the autonomous cortisol secretion group (18.2%, 2.3 ± 1.5 years), respectively (P = 0.019). Multivariate analysis only found significant association with age and the tumour size but if cortisol levels post-DST were analysed as a continuous variable it was significant as well. All deaths in autonomous cortisol secretion group were due to cancer not related to adrenal glands. Hypertension, cardiovascular disease and medications were more common in the possible and autonomous cortisol secretion group, especially in the former. More bilateral AIs and larger AI size were found in the two latter groups.

Conclusions

Patients with autonomous cortisol secretion had higher mortality than those with non-functioning AIs though cortisol levels post-DST as a continuous variable, age and tumour size were better predictor of mortality. Cardiovascular disease and osteoporosis medication seemed more prevalent in the possible and autonomous cortisol secretion groups, especially in the former.
Literature
1.
go back to reference G. Di Dalmazi, R. Pasquali, F. Beuschlein, M. Reincke, Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur. J. Endocrinol. 173(4), 61–71 (2015)CrossRef G. Di Dalmazi, R. Pasquali, F. Beuschlein, M. Reincke, Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur. J. Endocrinol. 173(4), 61–71 (2015)CrossRef
2.
go back to reference N. I. H. Consensus and S. Statements, NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (‘incidentaloma’). NIH Consens State Sci. Statements 19(2), 1–25 (2002) N. I. H. Consensus and S. Statements, NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (‘incidentaloma’). NIH Consens State Sci. Statements 19(2), 1–25 (2002)
3.
go back to reference M. Fassnacht, W. Arlt, I. Bancos, I. Dralle, Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 175(2), 1–34 (2016)CrossRef M. Fassnacht, W. Arlt, I. Bancos, I. Dralle, Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 175(2), 1–34 (2016)CrossRef
4.
go back to reference M. Terzolo, G. Osella, A. Alì, G. Borretta, F. Cesario, P. Paccotti, Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin. Endocrinol. 48(1), 89–97 (1998)CrossRef M. Terzolo, G. Osella, A. Alì, G. Borretta, F. Cesario, P. Paccotti, Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin. Endocrinol. 48(1), 89–97 (1998)CrossRef
5.
go back to reference M. Zeiger, G.B. Thompson, Q.-Y. Duh, A.H. Hamrahian, P. Angelos, D. Elaraj, E. Fishman, The American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15(1), 1–20 (2009)CrossRefPubMed M. Zeiger, G.B. Thompson, Q.-Y. Duh, A.H. Hamrahian, P. Angelos, D. Elaraj, E. Fishman, The American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15(1), 1–20 (2009)CrossRefPubMed
6.
go back to reference M. Debono, J. Newell-Price, Subclinical hypercortisolism in adrenal incidentaloma. Curr. Opin. Endocrinol. Diabetes. Obes. 22(3), 185–192 (2015) M. Debono, J. Newell-Price, Subclinical hypercortisolism in adrenal incidentaloma. Curr. Opin. Endocrinol. Diabetes. Obes. 22(3), 185–192 (2015)
7.
go back to reference M. Debono, M. Bradburn, M. Bull, B. Harrison, R.J. Ross, J. Newell-Price, Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99(12), 4462–4470 (2014)CrossRefPubMedPubMedCentral M. Debono, M. Bradburn, M. Bull, B. Harrison, R.J. Ross, J. Newell-Price, Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99(12), 4462–4470 (2014)CrossRefPubMedPubMedCentral
8.
go back to reference H. Falhammar, L. Frisen, A.L. Hirschberg, C. Norrby, C. Almqvist, A. Nordenskjold, A. Nordenstrom, Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. J. Clin. Endocrinol. Metab. 100(9), 3520–3528 (2015)CrossRefPubMed H. Falhammar, L. Frisen, A.L. Hirschberg, C. Norrby, C. Almqvist, A. Nordenskjold, A. Nordenstrom, Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. J. Clin. Endocrinol. Metab. 100(9), 3520–3528 (2015)CrossRefPubMed
9.
go back to reference J. Patrova, I. Jarocka, H. Wahrenberg, H. Falhammar, Clinical outcomes in adrenal incidentaloma: experience from one center. Endocr. Pract. 21(8), 870–877 (2015)CrossRefPubMed J. Patrova, I. Jarocka, H. Wahrenberg, H. Falhammar, Clinical outcomes in adrenal incidentaloma: experience from one center. Endocr. Pract. 21(8), 870–877 (2015)CrossRefPubMed
10.
go back to reference L. Barzon, M. Boscaro, Diagnosis and management of adrenal incidentalomas. J. Urol. 163(2), 398–407 (2000)CrossRefPubMed L. Barzon, M. Boscaro, Diagnosis and management of adrenal incidentalomas. J. Urol. 163(2), 398–407 (2000)CrossRefPubMed
11.
go back to reference B. Bülow, S. Jansson, C. Juhlin, L. Steen, M. Thorén, H. Wahrenberg, S. Valdemarsson, B. Wängberg, B. Ahrén, Adrenal incidentaloma-Follow up results from a Swedish prospective study. Eur. J. Endocrinol. 154(3), 419–423 (2006)CrossRefPubMed B. Bülow, S. Jansson, C. Juhlin, L. Steen, M. Thorén, H. Wahrenberg, S. Valdemarsson, B. Wängberg, B. Ahrén, Adrenal incidentaloma-Follow up results from a Swedish prospective study. Eur. J. Endocrinol. 154(3), 419–423 (2006)CrossRefPubMed
12.
go back to reference H. Yeomans, J. Calissendorff, C. Volpe, H. Falhammar, B. Mannheimer, Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study. BMC Endocr. Disord. 15(6), 1–6 (2015) H. Yeomans, J. Calissendorff, C. Volpe, H. Falhammar, B. Mannheimer, Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study. BMC Endocr. Disord. 15(6), 1–6 (2015)
13.
go back to reference L. Barzon, C. Scaroni, N. Sonino, F. Fallo, Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 84(2), 520–526 (1999)PubMed L. Barzon, C. Scaroni, N. Sonino, F. Fallo, Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 84(2), 520–526 (1999)PubMed
14.
go back to reference L. Barzon, F. Fallo, N. Sonino, M. Boscaro, Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocrinol. 146, 61–66 (2002) L. Barzon, F. Fallo, N. Sonino, M. Boscaro, Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocrinol. 146, 61–66 (2002)
15.
go back to reference R. Libè, C. Dall’Asta, L. Barbetta, A. Baccarelli, P. Beck-Peccoz, B. Ambrosi, Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 147(4), 489–494 (2002)CrossRefPubMed R. Libè, C. Dall’Asta, L. Barbetta, A. Baccarelli, P. Beck-Peccoz, B. Ambrosi, Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 147(4), 489–494 (2002)CrossRefPubMed
16.
go back to reference G. Di Dalmazi, V. Vicennati, S. Garelli, E. Casadio, E. Rinaldi, E. Giampalma, C. Mosconi, R. Golfieri, A. Paccapelo, U. Pagotto, R. Pasquali, Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2(5), 396–405 (2014)CrossRefPubMed G. Di Dalmazi, V. Vicennati, S. Garelli, E. Casadio, E. Rinaldi, E. Giampalma, C. Mosconi, R. Golfieri, A. Paccapelo, U. Pagotto, R. Pasquali, Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2(5), 396–405 (2014)CrossRefPubMed
17.
go back to reference H.C. Abercrombie, J. Giese-Davis, S. Sephton, E.S. Epel, J.M. Turner-Cobb, M. Spiegel, Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 29(8), 1082–1092 (2004)CrossRefPubMed H.C. Abercrombie, J. Giese-Davis, S. Sephton, E.S. Epel, J.M. Turner-Cobb, M. Spiegel, Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 29(8), 1082–1092 (2004)CrossRefPubMed
18.
go back to reference S.E. Sephton, F.S. Dhabhar, A.S. Keuroghlian, J. Giese-Davis, B.S. McEwen, A.C. Ionan, D. Spiegel, Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav. Immun. 23(8), 1148–1155 (2009)CrossRefPubMed S.E. Sephton, F.S. Dhabhar, A.S. Keuroghlian, J. Giese-Davis, B.S. McEwen, A.C. Ionan, D. Spiegel, Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav. Immun. 23(8), 1148–1155 (2009)CrossRefPubMed
19.
go back to reference E. Filipski, V.M. King, X. Li, T.G. Granda, M.-C. Mormont, X. Liu, B. Claustrat, M.H. Hastings, F. Lévi, Host circadian clock as a control point in tumor progression. J. Natl Cancer Inst. 94(9), 690–697 (2002)CrossRefPubMed E. Filipski, V.M. King, X. Li, T.G. Granda, M.-C. Mormont, X. Liu, B. Claustrat, M.H. Hastings, F. Lévi, Host circadian clock as a control point in tumor progression. J. Natl Cancer Inst. 94(9), 690–697 (2002)CrossRefPubMed
20.
go back to reference R.M. Sapolsky, T.M. Donnelly, Vulnerability to Stress-Induced Tumor Growth Increases with Age in Rats: role of glucocorticoids. Endocrinology 117(2), 662–666 (1985) R.M. Sapolsky, T.M. Donnelly, Vulnerability to Stress-Induced Tumor Growth Increases with Age in Rats: role of glucocorticoids. Endocrinology 117(2), 662–666 (1985)
21.
go back to reference T.J. Moran, S. Gray, C.A. Mikosz, S.D. Conzen, The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 60(4), 867–872 (2000)PubMed T.J. Moran, S. Gray, C.A. Mikosz, S.D. Conzen, The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 60(4), 867–872 (2000)PubMed
22.
go back to reference T.M. Rae, S.H. Hillier, Steroid signalling in the ovarian surface epithelium. Trends Endocrinol. Metab. 16(7), 327–333 (2005)CrossRefPubMed T.M. Rae, S.H. Hillier, Steroid signalling in the ovarian surface epithelium. Trends Endocrinol. Metab. 16(7), 327–333 (2005)CrossRefPubMed
23.
go back to reference G. Di Dalmazi, V. Vicennati, E. Rinaldi, A.M. Morselli-Labate, E. Giampalma, C. Mosconi, U. Pagotto, R. Pasquali, Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur. J. Endocrinol. 166(4), 669–677 (2012)CrossRefPubMed G. Di Dalmazi, V. Vicennati, E. Rinaldi, A.M. Morselli-Labate, E. Giampalma, C. Mosconi, U. Pagotto, R. Pasquali, Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur. J. Endocrinol. 166(4), 669–677 (2012)CrossRefPubMed
24.
go back to reference R. Rossi, L. Tauchmanova, A. Luciano, M.D.I. Martino, C. Battista, O. Molecolare, Subclinical cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metabol. 85(4), 1440–1448 (2000) R. Rossi, L. Tauchmanova, A. Luciano, M.D.I. Martino, C. Battista, O. Molecolare, Subclinical cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metabol. 85(4), 1440–1448 (2000)
25.
go back to reference G. Di Dalmazi, Update on the risks of benign adrenocortical incidentalomas. Curr. Opin. Endocrinol. Diabetes Obes. 193–199, (2017) G. Di Dalmazi, Update on the risks of benign adrenocortical incidentalomas. Curr. Opin. Endocrinol. Diabetes Obes. 193–199, (2017)
26.
go back to reference D. Lopez, M.A. Luque-Fernandez, A. Steele, G.K. Adler, A. Turchin, A. Vaidya, ‘Nonfunctional’ adrenal tumors and the risk for incident diabetes and cardiovascular outcomes. Ann. Intern. Med. 165(8), 533–542 (2016) D. Lopez, M.A. Luque-Fernandez, A. Steele, G.K. Adler, A. Turchin, A. Vaidya, ‘Nonfunctional’ adrenal tumors and the risk for incident diabetes and cardiovascular outcomes. Ann. Intern. Med. 165(8), 533–542 (2016)
27.
go back to reference H. Olsen, E. Nordenström, A. Bergenfelz, U. Nyman, S. Valdemarsson, E. Palmqvist, Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42(1), 164–172 (2012)CrossRefPubMed H. Olsen, E. Nordenström, A. Bergenfelz, U. Nyman, S. Valdemarsson, E. Palmqvist, Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42(1), 164–172 (2012)CrossRefPubMed
28.
go back to reference A.S. Mihailidou, T.Y.L. Le, M. Mardini, Y.W. Funder, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54(6), 1306–1312 (2009)CrossRefPubMed A.S. Mihailidou, T.Y.L. Le, M. Mardini, Y.W. Funder, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54(6), 1306–1312 (2009)CrossRefPubMed
29.
go back to reference M. De Leo, R. Pivonello, R.S. Auriemma, A. Cozzolino, P. Vitale, C. Simeoli, M.C. De Martino, G. Lombardi, A. Colao, Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 92(1), 50–54 (2010)CrossRefPubMed M. De Leo, R. Pivonello, R.S. Auriemma, A. Cozzolino, P. Vitale, C. Simeoli, M.C. De Martino, G. Lombardi, A. Colao, Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 92(1), 50–54 (2010)CrossRefPubMed
30.
go back to reference A. Toniato, I. Merante-Boschin, G. Opocher, M.R. Pelizzo, F. Schiavi, E. Ballotta, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 249(3), 388–391 (2009)CrossRefPubMed A. Toniato, I. Merante-Boschin, G. Opocher, M.R. Pelizzo, F. Schiavi, E. Ballotta, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 249(3), 388–391 (2009)CrossRefPubMed
31.
go back to reference I.I. Androulakis, G.A. Kaltsas, G.E. Kollias, A.C. Markou, A.K. Gouli, D.A. Thomas, K.I. Alexandraki, C.M. Papamichael, D.J. Hadjidakis, G.P. Piaditis, Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 99(8), 2754–2762 (2014)CrossRefPubMed I.I. Androulakis, G.A. Kaltsas, G.E. Kollias, A.C. Markou, A.K. Gouli, D.A. Thomas, K.I. Alexandraki, C.M. Papamichael, D.J. Hadjidakis, G.P. Piaditis, Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 99(8), 2754–2762 (2014)CrossRefPubMed
Metadata
Title
Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center
Authors
Jekaterina Patrova
Magnus Kjellman
Hans Wahrenberg
Henrik Falhammar
Publication date
01-11-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1400-8

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.